Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Palisade Bio (PALI) Receivables - Other (2016 - 2023)

Palisade Bio has reported Receivables - Other over the past 7 years, most recently at $105625.0 for Q4 2023.

  • Quarterly Receivables - Other fell 25.22% to $105625.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $105625.0 through Dec 2023, down 25.22% year-over-year, with the annual reading at $105625.0 for FY2023, 25.22% down from the prior year.
  • Receivables - Other was $105625.0 for Q4 2023 at Palisade Bio, roughly flat from $105625.0 in the prior quarter.
  • Over five years, Receivables - Other peaked at $229000.0 in Q1 2019 and troughed at $105625.0 in Q2 2023.
  • The 4-year median for Receivables - Other is $229000.0 (2019), against an average of $187375.0.
  • Year-over-year, Receivables - Other skyrocketed 267.88% in 2019 and then fell 25.22% in 2023.
  • A 4-year view of Receivables - Other shows it stood at $229000.0 in 2019, then changed by 0.0% to $229000.0 in 2020, then crashed by 38.32% to $141250.0 in 2022, then decreased by 25.22% to $105625.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Receivables - Other are $105625.0 (Q4 2023), $105625.0 (Q3 2023), and $105625.0 (Q2 2023).